Can-Fite BioPharma (CANF) - Quarterly EPS earnings growth
The trend toward selective adenosine receptor targeting in affected tissues ensures the safety of Can-Fite BioPharma therapies. The quarterly EPS growth efficiency metric demonstrates current volatility, with 67.00 serving as the current marker for the indicator. Outlooks are based on the commercialization of namadesone for liver cancer, and the completion of late-stage clinical trials brings the company closer to market entry.
%20Year-over-year%20net%20earnings%20per%20share%20growth%20for%20the%20last%2012%20months&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_CANF_-_Can-Fite-BioPharma_-_Year-over-year-net-earnings-per-share-growth-for-the-last-12-months "Can-Fite BioPharma, Ltd. (CANF) Year-over-year earnings per share growth for the last twelve months: for the period 07/04/2022 - 11/11/2026 | 👁️GURU.Markets👁️")
Analytical breakdowns for Can-Fite BioPharma
- market value and analyst target forecast:
- market capitalization indicators:
- balance sheet net asset value indicators:
- debt and liquidity details:
Debt to Equity Can-Fite BioPharma|CANF - Long-Term Liabilities to Capital|Short-Term Debt to Capital Can-Fite BioPharma|CANF - Company Total Indebtedness|Debt to Book Value Can-Fite BioPharma, Ltd.|CANF - Long-Term Debt|Company Current Liabilities Can-Fite BioPharma|Quick Liquidity Indicator canfite.com
- earnings and market multiples details:
CANF - Profit After Payment of Taxes|Projected Future Earnings Can-Fite BioPharma|CANF - Company Value to Net Income|Forward P/E Multiple Can-Fite BioPharma, Ltd.|CANF - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Can-Fite BioPharma, Ltd.|CANF - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Can-Fite BioPharma|CANF - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months canfite.com|CANF - Earnings per share trend in current year|Expected earnings per share growth for next year Can-Fite BioPharma
Fundamental company analysis:Can-Fite BioPharma Ltd., CANF
High expenditures by Can-Fite BioPharma (CANF) during the final stages of oncology drug trials are placing significant pressure on capital, which directly impacts the net earnings per share trend. By analyzing the quarterly EPS growth vector, investors assess expense management efficiency and the risks of equity dilution during secondary offerings, utilizing this indicator as a barometer for the business's fundamental stability.
Analysis of competing companies
Incyte (INCY) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last 12 months HCM|NUVB (Nuvation Pharma) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Day One Biopharmaceuticals Inc (DAWN)|Year-over-year earnings per share growth for the last twelve months Monopar Therapeutics (MNPR)|INBX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months I-Mab Biopharma IMAB|Fennec Pharma - Year-over-year earnings per share growth for the last twelve months|HRTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Nuvectis Pharma, Inc|CHRS: Quarterly EPS earnings growth|Net earnings per share growth for the trailing year corbuspharma.com CRBP|Year-over-year net earnings per share growth for the last 12 months CRDF|Earnings per share growth in annualized terms for the last twelve months BeyondSpring, Inc. BYSI|Year-over-year net earnings per share growth for the last 12 months BCAB (BioAtla, Inc.)|LIXT (Lixte Biotechnology, Inc.) - Year-over-year earnings per one share growth for the last 12 months|Citius Pharmaceuticals, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months CLRB (cellectar.com)|BioLineRx - Quarterly EPS earnings growth|Year-over-year earnings per one share growth for the last 12 months APRE (Aprea Therapeutics)|KZIA: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Silexion Therapeutics (SLXN)|Year-over-year earnings per share growth for the last twelve months NuCana PLC|CMRX: Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth CYCC|Quarterly EPS earnings growth g1therapeutics.com (GTHX)|Year-over-year earnings per share growth for the last twelve months Kronos Bio Corp KRON|KTRA (Kintara Pharma) - Year-over-year net earnings per share trend for the last twelve months|ONCT: Year-over-year net earnings per share growth for the last 12 months|Earnings per share growth in annualized terms for the last twelve months portagebiotech.com
